Citations (92)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (28)
Ying Lan, Nan Yang, Yirong Wang, Yan Yang, Min Xu & Qin He. (2023) Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 2093-2103.
Read now
Read now
Alexandrosz Czira, Gema Requena, Victoria Banks, Robert Wood, Theo Tritton, Catherine M Castillo, Jie Yeap, Rosie Wild, Chris Compton, Kieran J Rothnie, Felix Herth, Jennifer K Quint & Afisi S Ismaila. (2023) Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 643-659.
Read now
Read now
Ji Won Park, Yoonki Hong, Chin Kook Rhee, Hye Sook Choi, Kyungjoo Kim, Kwang Ha Yoo, Ki-Suck Jung & Joo Hun Park. (2023) The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 733-743.
Read now
Read now
Qing Song, Ling Lin, Aiyuan Zhou, Wei Cheng, Cong Liu, Yating Peng, Zijing Zhou, Yuqin Zeng, Dingding Deng, Dan Liu, Zhiping Yu, Yan Chen, Shan Cai & Ping Chen. (2023) The effects of different inhalation therapies on less symptomatic chronic obstructive pulmonary disease patients in a Chinese population: a real-world study. Annals of Medicine 55:1, pages 1317-1324.
Read now
Read now
Stephen A. Brunton & D. Kyle Hogarth. (2023) Overuse of long-acting β2-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns. Postgraduate Medicine 0:0, pages 1-19.
Read now
Read now
Yanling Ding, Lina Sun, Ying Wang, Jing Zhang & Yahong Chen. (2022) Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 1051-1067.
Read now
Read now
Soham Shukla, Dhvani Shah, Alan Martin, Nancy A Risebrough, Robyn Kendall, Claus F Vogelmeier, Isabelle Boucot, Lee Tombs, Leif Bjermer, Paul W Jones, Edward Kerwin, Chris Compton, François Maltais, David A Lipson & Afisi S Ismaila. (2021) Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 3105-3118.
Read now
Read now
Arschang Valipour, Sergey Avdeev, Adam Barczyk, Valentina Bayer, Zvi Fridlender, Mariela Georgieva, Ondřej Kudela, Alexey Medvedchikov, Ramona Miron, Maria Sanzharovskaya, Virginija Šileikienė, Jurij Šorli, Marc Spielmanns & Zsuzsanna Szalai. (2021) Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 615-628.
Read now
Read now
Leif Bjermer, Isabelle H Boucot, François Maltais, Edward M Kerwin, Ian P Naya, Lee Tombs, Paul W Jones, Chris Compton, David A Lipson & Claus F Vogelmeier. (2021) Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 1939-1956.
Read now
Read now
Anthony D. D’Urzo, Dave Singh, James F. Donohue, Kenneth R. Chapman & Robert A. Wise. (2021) Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. Expert Review of Respiratory Medicine 15:9, pages 1093-1106.
Read now
Read now
Gerard Criner & Sean Duffy. (2021) Reducing and managing chronic obstructive pulmonary disease exacerbations with tiotropium + olodaterol. Current Medical Research and Opinion 37:2, pages 275-284.
Read now
Read now
Carlos Cabrera López, Enrique Mascarós, Angel Azpeitia & Elena Villarrubia. (2020) A Simplified Algorithm for the Diagnosis, Treatment, and Management of COPD in Routine Primary Care Practice. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 3347-3355.
Read now
Read now
Chad Moretz, Beth Hahn, John White, Alyssa Goolsby Hunter, Breanna Essoi, Caitlin Elliott & Riju Ray. (2020) Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2715-2725.
Read now
Read now
Chad Moretz, Ashley L Cole, George Mu, Benjamin Wu, Amy Guisinger, Yunhao Liu, Beth Hahn & Lee Baylis. (2020) Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2207-2215.
Read now
Read now
Jesús Recio Iglesias, Jesús Díez-Manglano, Francisco López García, José Antonio Díaz Peromingo, Pere Almagro & José Manuel Varela Aguilar. (2020) Management of the COPD Patient with Comorbidities: An Experts Recommendation Document. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1015-1037.
Read now
Read now
G. Hillas, A. Papaporfyriou, K. Dimakou & A. I. Papaioannou. (2020) Pharmacological treatment of stable COPD: need for a simplified approach. Postgraduate Medicine 132:2, pages 126-131.
Read now
Read now
Neil S. Skolnik, Trang Susan Nguyen, Aarisha Shrestha, Riju Ray, Thomas C. Corbridge & Stephen A. Brunton. (2020) Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators. Postgraduate Medicine 132:2, pages 198-205.
Read now
Read now
Timothy E Albertson, Willis S Bowman, Richart W Harper, Regina M Godbout & Susan Murin. (2019) Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1251-1265.
Read now
Read now
Konstantin Tachkov, Maria Dimitrova, Konstantin Mitov, Alexandra Savova, Maria Kamusheva, Jordan Dimitrov, Manoela Manova, Daniela Grekova & Valentina Petkova. (2019) Micro and macro analysis on the burden of COPD hospitalizations on the Bulgarian healthcare system. Biotechnology & Biotechnological Equipment 33:1, pages 1-11.
Read now
Read now
Edward Kerwin & Gary T. Ferguson. (2018) An overview of glycopyrrolate/eFlow® CS in COPD. Expert Review of Respiratory Medicine 12:6, pages 447-459.
Read now
Read now
Paola Rogliani, Josuel Ora, Maria Gabriella Matera, Mario Cazzola & Luigino Calzetta. (2018) The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opinion on Drug Safety 17:6, pages 589-596.
Read now
Read now
Maria Gabriella Matera, Luigino Calzetta, Ermanno Puxeddu, Paola Rogliani & Mario Cazzola. (2018) A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety 17:5, pages 509-517.
Read now
Read now
Keiji Oishi, Tsunahiko Hirano, Kazuki Hamada, Sho Uehara, Ryo Suetake, Yoshikazu Yamaji, Kosuke Ito, Maki Asami-Noyama, Nobutaka Edakuni & Kazuto Matsunaga. (2018) Characteristics of 2017 GOLD COPD group A: a multicenter cross-sectional CAP study in Japan. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3901-3907.
Read now
Read now
Donald P Tashkin & Charlie Strange. (2018) Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 2587-2601.
Read now
Read now
Paola Rogliani, Luigino Calzetta, Fulvio Braido, Mario Cazzola, Enrico Clini, Girolamo Pelaia, Andrea Rossi, Nicola Scichilone & Fabiano Di Marco. (2018) LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3115-3130.
Read now
Read now
Claus F Vogelmeier, Kenneth R Chapman, Marc Miravitlles, Nicolas Roche, Jørgen Vestbo, Chau Thach, Donald Banerji, Robert Fogel, Francesco Patalano, Petter Olsson, Konstantinos Kostikas & Jadwiga A Wedzicha. (2018) Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 1125-1134.
Read now
Read now
Paola Rogliani, Maria Gabriella Matera, Josuel Ora, Mario Cazzola & Luigino Calzetta. (2017) The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 3469-3485.
Read now
Read now
Josefin Sundh, Joakim Åberg, Mikael Hasselgren, Scott Montgomery, Björn Ställberg, Karin Lisspers & Christer Janson. (2017) Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014. European Clinical Respiratory Journal 4:1.
Read now
Read now
Articles from other publishers (64)
Felisbela Gomes & Shih-Lung Cheng. (2023) Pathophysiology, Therapeutic Targets, and Future Therapeutic Alternatives in COPD: Focus on the Importance of the Cholinergic System. Biomolecules 13:3, pages 476.
Crossref
Crossref
Mingjin Yang, Yishi Li, Youfan Jiang, Shuliang Guo, Jian-Qing He & Don D. Sin. (2023) Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. European Respiratory Journal 61:2, pages 2200302.
Crossref
Crossref
Marc Miravitlles, Tomotaka Kawayama & Michael Dreher. (2022) LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations. Journal of Clinical Medicine 11:22, pages 6623.
Crossref
Crossref
Afisi S. Ismaila, Katrin Haeussler, Alexandrosz Czira, Vanita Tongbram, Mia Malmenäs, Jatin Agarwal, Maria Nassim, Marija Živković-Gojović, Yunrong Shen, Xinzhe Dong, Maria Duarte, Chris Compton, Claus F. Vogelmeier & David M. G. Halpin. (2022) Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis. Advances in Therapy 39:11, pages 4961-5010.
Crossref
Crossref
Joseph J Cuthbert, Pierpaolo Pellicori & Andrew L Clark. (2022) Optimal Management of Heart Failure and Chronic Obstructive Pulmonary Disease: Clinical Challenges. International Journal of General Medicine Volume 15, pages 7961-7975.
Crossref
Crossref
Ricardo G. Figueiredo, Lucas F. Araujo & José de Bessa Junior. (2022) The Role of Dual Bronchodilation and the Conscientious Use of Inhaled Corticosteroid in COPD. Sinusitis 6:2, pages 32-35.
Crossref
Crossref
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
271
299
.
Yoshimasa MIZUNO, Koyo SHIRAHASHI, Hirotaka YAMAMOTO, Mitsuyoshi MATSUMOTO, Yusaku MIYAMOTO, Hiroyasu KOMURO, Kiyohiko HAGIWARA, Kiyoshi DOI & Hisashi IWATA. (2021) Efficacy of preoperative inhaled LAMA/LABA combinations in patients with lung cancer and untreated COPD. Minerva Surgery 76:6.
Crossref
Crossref
Osman Savran, Nina Godtfredsen, Torben Sørensen, Christian Jensen & Charlotte Suppli Ulrik. (2021) COPD patients prescribed inhaled corticosteroid in primary care: time for re-assessment based on exacerbation rate and blood eosinophils?. Respiratory Research 22:1.
Crossref
Crossref
Paschalis Steiropoulos, Stavros Tryfon, Christos Kyriakopoulos, Konstantinos Bartziokas & Konstantinos Kostikas. (2021) Evaluation of the Clinical Effectiveness of the Salmeterol/Fluticasone Fixed-Dose Combination Delivered via the Elpenhaler® Device in Greek Patients with Chronic Obstructive Pulmonary Disease and Comorbidities: The AEOLOS Study. Journal of Personalized Medicine 11:11, pages 1159.
Crossref
Crossref
A. I. Sinopalnikov. (2021) Pharmacotherapeutic strategy for COPD patients: focus on dual bronchodilators. Meditsinskiy sovet = Medical Council:16, pages 38-44.
Crossref
Crossref
Leif H. Bjermer, Isabelle H. Boucot, Claus F. Vogelmeier, François Maltais, Paul W. Jones, Lee Tombs, Chris Compton, David A. Lipson & Edward M. Kerwin. (2021) Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial. Advances in Therapy 38:9, pages 4815-4835.
Crossref
Crossref
Martine Hoogendoorn, Isaac Corro Ramos, Stéphane Soulard, Jennifer Cook, Erkki Soini, Emma Paulsson & Maureen Rutten-van Mölken. (2021) Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study. BMJ Open 11:8, pages e049675.
Crossref
Crossref
Swetha R PalliBin XieBenjamin ChastekCaitlin A ElliottLindsay G S Bengtson. (2021) Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies. Journal of Managed Care & Specialty Pharmacy 27:7, pages 810-824.
Crossref
Crossref
Dave Singh, James F. Donohue, Isabelle H. Boucot, Neil C. Barnes, Chris Compton & Fernando J. Martinez. (2021)
Future concepts in bronchodilation for COPD: dual-
versus
monotherapy
. European Respiratory Review 30:160, pages 210023.
Crossref
Crossref
Jennifer K. Quint, Jukka Montonen, Daina B. Esposito, Xintong He, Leslie Koerner, Laura Wallace, Alberto de la Hoz & Marc Miravitlles. (2021) Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database. Advances in Therapy 38:5, pages 2249-2270.
Crossref
Crossref
Emil Scosyrev, Richard van Zyl-Smit, Huib Kerstjens, Christian Gessner, Oliver Kornmann, Devendra Jain, Elodie Aubrun, Peter D'Andrea, Motoi Hosoe, Abhijit Pethe & Dominic Brittain. (2021) Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials. Respiratory Medicine 180, pages 106311.
Crossref
Crossref
Hong Chen, Ke Wang, Tao Yuan, Xiaoming Wang, Lan Huanng, Zhenhuan Jiang, Keyang Chen & Yuejun Du. (2021) Dual bronchodilator versus inhaled corticosteroid/long-acting β2-agonist in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. International Immunopharmacology 93, pages 107447.
Crossref
Crossref
Tarek M. Mostafa, Gamal A. El-Azab, Ghada A. Atia & Noran S. Lotfy. (2021) The Effectiveness of 3 Combined Therapeutic Regimens in Egyptian Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Randomized Double-Blind Prospective Pilot Study. Current Therapeutic Research 94, pages 100625.
Crossref
Crossref
Sushweta Mahalanobish, Sayanta Dutta & Parames C. Sil. 2021. Targeting Cellular Signalling Pathways in Lung Diseases. Targeting Cellular Signalling Pathways in Lung Diseases
163
190
.
Jinping Zheng, Jin-fu Xu, Martin Jenkins, Pryseley Nkouibert Assam, Lijiao Wang & Brian J. Lipworth. (2020) Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials. Respiratory Research 21:1.
Crossref
Crossref
Hyun Woo Lee, Jimyung Park, Eun Jin Jang & Chang-Hoon Lee. (2020) Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. Respiratory Research 21:1.
Crossref
Crossref
Roland Buhl, Alberto de la Hoz, Wenqiong Xue, Dave Singh & Gary T. Ferguson. (2020) Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials. Advances in Therapy 37:10, pages 4175-4189.
Crossref
Crossref
Shigeo Muro, Hajime Yoshisue, Konstantinos Kostikas, Petter Olsson, Pritam Gupta & Jadwiga A. Wedzicha. (2019) Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis. Respirology 25:4, pages 393-400.
Crossref
Crossref
Vicente Benavides-Cordoba, Sebastian Aviles, Camila Ascuntar, Lina Orozco, Ricardo Mosquera & Julian Rivera. (2020) Dual use of bronchodilators versus monotherapy, and its impact on pulmonary rehabilitation in COPD patients. Pulmonary Pharmacology & Therapeutics 61, pages 101898.
Crossref
Crossref
María Montes de Oca, Maria Victorina López Varela, Agustín Acuña, Eduardo Schiavi, Alejandro Casas, Antonio Tokumoto, Carlos A. Torres Duque, Alejandra Ramírez-Venegas, Gabriel García, Aquiles Camelier, Miguel Bergna, Mark Cohen, Efraín Sanchez-Angarita, Santiago Guzmán, Karen Czischke, Manuel Barros & Alejandra Rey. (2020) Incorporando nuevas evidencias sobre medicamentos inhalados en la EPOC. Asociación Latinoamericana de Tórax (ALAT) 2019. Archivos de Bronconeumología 56:2, pages 106-113.
Crossref
Crossref
Maria Montes de Oca, Maria Victorina López Varela, Agustín Acuña, Eduardo Schiavi, Alejandro Casas, Antonio Tokumoto, Carlos A. Torres Duque, Alejandra Ramírez-Venegas, Gabriel García, Aquiles Camelier, Miguel Bergna, Mark Cohen, Efraín Sanchez-Angarita, Santiago Guzmán, Karen Czischke, Manuel Barros & Alejandra Rey. (2020) Incorporating new evidence on inhaled medications in COPD. The latin American chest association (ALAT) 2019. Archivos de Bronconeumología (English Edition) 56:2, pages 106-113.
Crossref
Crossref
Ching-Yi Chen, Wang-Chun Chen, Chi-Hsien Huang, Yi-Ping Hsiang, Chau-Chyun Sheu, Yung-Che Chen, Meng-Chih Lin, Kuo-An Chu, Cheng-Hung Lee & Yu-Feng Wei. (2020)
LABA/LAMA fixed-dose combinations
versus
LAMA monotherapy in the prevention of COPD exacerbations: a systematic review and meta-analysis
. Therapeutic Advances in Respiratory Disease 14, pages 175346662093719.
Crossref
Crossref
Afroditi K. Boutou, Georgia G. Pitsiou, Ioannis Stanopoulos, Theodoros Kontakiotis, Despoina Papakosta & Ioannis Kioumis. (2020) Regular Treatment and Disease Outcomes in Patients with Chronic Obstructive Pulmonary Disease Group A. Respiration 99:5, pages 458-458.
Crossref
Crossref
Hannah R. Whittaker, Debbie Jarvis, Mohamed R. Sheikh, Steven J. Kiddle & Jennifer K. Quint. (2019) Inhaled corticosteroids and FEV1 decline in chronic obstructive pulmonary disease: a systematic review. Respiratory Research 20:1.
Crossref
Crossref
Nicolas Roche, Anestis Antoniadis, David Hess, Pei Zhi Li, Eric Kelkel, Sylvie Leroy, Christophe Pison, Pierre-Régis Burgel & Bernard Aguilaniu. (2019) Are there specific clinical characteristics associated with physician’s treatment choices in COPD?. Respiratory Research 20:1.
Crossref
Crossref
Luigino Calzetta, Fabiano Di Marco, Francesco Blasi, Mario Cazzola, Stefano Centanni, Claudio Micheletto, Andrea Rossi & Paola Rogliani. (2019) Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. Pulmonary Pharmacology & Therapeutics 59, pages 101855.
Crossref
Crossref
Aernout Haarst, Lorcan McGarvey & Sabina Paglialunga. (2019)
Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease:
US
and
EU
Perspectives
. Clinical Pharmacology & Therapeutics 106:6, pages 1222-1235.
Crossref
Crossref
Tanja Fens, Simon van der Pol, Janwillem W.H. Kocks, Maarten J. Postma & Job F.M. van Boven. (2019) Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice. Value in Health 22:10, pages 1092-1101.
Crossref
Crossref
Nicolas Roche, Bernard Aguilaniu, Pei Zhi Li & David Hess. (2019) Trends over time in COPD treatment choices by respiratory physicians: An analysis from the COLIBRI-COPD French cohort. Respiratory Medicine 156, pages 8-14.
Crossref
Crossref
Flora Pirozzi, Kai Ren, Alessandra Murabito & Alessandra Ghigo. (2019) PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy. Current Medicinal Chemistry 26:16, pages 2791-2800.
Crossref
Crossref
Anthony D’Urzo, Kenneth R. Chapman, James F. Donohue, Peter Kardos, M. Reza Maleki-Yazdi & David Price. (2019) Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD. Pulmonary Therapy 5:1, pages 23-41.
Crossref
Crossref
Claudia C Dobler, Magdoleen H Farah, Allison S Morrow, Mouaz Alsawas, Raed Benkhadra, Bashar Hasan, Larry J Prokop, Zhen Wang & M Hassan Murad. (2019) Treatment of stable chronic obstructive pulmonary disease: protocol for a systematic review and evidence map. BMJ Open 9:5, pages e027935.
Crossref
Crossref
Mario Malerba, Valentina Foci, Filippo Patrucco, Patrizia Pochetti, Matteo Nardin, Corrado Pelaia & Alessandro Radaeli. (2019) Single Inhaler LABA/LAMA for COPD. Frontiers in Pharmacology 10.
Crossref
Crossref
Chin Kook Rhee, Hajime Yoshisue & Rahul Lad. (2019) Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives. Advances in Therapy 36:3, pages 495-519.
Crossref
Crossref
Anthony D. D’Urzo, Dave Singh, James F. Donohue & Kenneth R. Chapman. (2019) Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. Therapeutic Advances in Respiratory Disease 13, pages 175346661985072.
Crossref
Crossref
Eric Derom, Guy G. Brusselle & Guy F. Joos. (2019) The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects. Therapeutic Advances in Respiratory Disease 13, pages 175346661984342.
Crossref
Crossref
Camilla Boslev Baarnes, Betina H Thuesen, Allan Linneberg, Amalie S Ustrup, Signe Knag Pedersen & Charlotte Suppli Ulrik. (2019)
Predictors of accelerated FEV
1
decline in adults with airflow limitation—Findings from the Health2006 cohort
. Chronic Respiratory Disease 16, pages 147997311983827.
Crossref
Crossref
Michael G. Crooks, Joanne L. Thompson, Helena Cummings, Karen Watkins, Nicola Jackson, Shaneen Platten, Cheryl Evans & Shoaib Faruqi. (2019) Hidden morbidity: The results of a collaborative community chronic obstructive pulmonary disease screening initiative. The Clinical Respiratory Journal 13:1, pages 43-49.
Crossref
Crossref
Han Ni, Soe Moe, Zay Soe, Kay Thi Myint & K Neelakantan Viswanathan. (2018) Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
Yuji Oba, Edna Keeney, Namratta Ghatehorde & Sofia Dias. (2018) Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
Hetal Dhruve. (2018) Chronic obstructive pulmonary disease: diagnosis and management. Independent Nurse 2018:12, pages 17-22.
Crossref
Crossref
Dhvani Shah, Maurice Driessen, Nancy Risebrough, Timothy Baker, Ian Naya, Andrew Briggs & Afisi S. Ismaila. (2018) Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Crossref
Peter A. Frith, Samiha Ashmawi, Srikanth Krishnamurthy, Alev Gurgun, Sashka Hristoskova, Virginia Pilipovic, Anna Marie Hamann, Arthur Backer, Petter Olsson, Konstantinos Kostikas & Dina V. Diaz. (2018) Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non‐frequently exacerbating COPD patients: The FLASH randomized controlled trial. Respirology 23:12, pages 1152-1159.
Crossref
Crossref
A. I. Sinopalnikov. (2018) Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice. Medical Council:15, pages 96-100.
Crossref
Crossref
Oliver Price, Chandra Sarkar & Shruthi Konda. (2018) An update on the use of inhaled therapy in COPD. Clinical Medicine 18:5, pages 387-390.
Crossref
Crossref
MeiLan K. Han, Riju Ray, Jason Foo, Chaienna Morel & Beth Hahn. (2018) Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD. npj Primary Care Respiratory Medicine 28:1.
Crossref
Crossref
Han-Rong Feng, Chao Zhang & Song-Min Ying. (2018) Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease. Chinese Medical Journal 131:16, pages 1894-1897.
Crossref
Crossref
Kenneth R. Chapman, John R. Hurst, Stefan-Marian Frent, Michael Larbig, Robert Fogel, Tadhg Guerin, Donald Banerji, Francesco Patalano, Pankaj Goyal, Pascal Pfister, Konstantinos Kostikas & Jadwiga A. Wedzicha. (2018) Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. American Journal of Respiratory and Critical Care Medicine 198:3, pages 329-339.
Crossref
Crossref
Antonio Anzueto & Marc Miravitlles. (2018) Considerations for the Correct Diagnosis of COPD and Its Management With Bronchodilators. Chest 154:2, pages 242-248.
Crossref
Crossref
S. N. Avdeev, A. S. Belevskiy, Z. R. Aisanov, V. V. Arkhipov, I. V. Leshchenko, S. I. Ovcharenko, A. I. Sinopal’nikov, A. A. Vizel’, A. V. Emel’yanov, A. V. Zhestkov, K. A. Zykov, N. A. Kuzubova, G. G. Prozorova, B. A. Chernyak, N. L. Shaporova & E. I. Shmelev. (2018) Possibilities to prevent acute exacerbation of chronic obstructive pulmonary disease using inhalational therapy. A Report of Expert Panel of Russian Respiratory Society. Russian Pulmonology 28:3, pages 368-380.
Crossref
Crossref
Marcia Regina Piuvezam, Laércia Karla Diega Paiva Ferreira, Talissa Mozzini Monteiro, Giciane Carvalho Vieira & Claudio Roberto Bezerra-Santos. 2018. Asthma Diagnosis and Management - Approach Based on Phenotype and Endotype. Asthma Diagnosis and Management - Approach Based on Phenotype and Endotype.
Alberto Papi, Konstantinos Kostikas, Jadwiga A. Wedzicha, Claus F. Vogelmeier, Nicolas Roche, Steven Shen, Donald Banerji, Robert Fogel, Francesco Patalano & Kenneth R. Chapman. (2018) Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study. American Journal of Respiratory and Critical Care Medicine 197:9, pages 1223-1226.
Crossref
Crossref
Paola Rogliani, Luigino Calzetta & Mario Cazzola. (2018) Is ICS–LAMA an alternative option to treat patients with COPD?. The Lancet Respiratory Medicine 6:5, pages 316-317.
Crossref
Crossref
Zhou Zhang, Joseph Gordon & Kasra Sedarati. (2018) Chronic Obstructive Pulmonary Disease: Recent Advances and Controversies in Inhaler Therapies. American Journal of Respiratory and Critical Care Medicine 197:7, pages 944-946.
Crossref
Crossref
Keisuke Miki, Kazuyuki Tsujino, Ryuya Edahiro, Seigo Kitada, Mari Miki, Kenji Yoshimura, Hiroyuki Kagawa, Yohei Oshitani, Yuko Ohara, Yuki Hosono, Hiroyuki Kurebe & Ryoji Maekura. (2018) Exercise tolerance and balance of inspiratory-to-expiratory muscle strength in relation to breathing timing in patients with chronic obstructive pulmonary disease. Journal of Breath Research 12:3, pages 036008.
Crossref
Crossref
Yi-Han Hsiao, Ching-Min Tseng, Kang-Cheng Su, Wen-Chian Chen, Mo-Tzu Wu, Yu-Chung Wu, Shi-Chuan Chang, Yu-Chin Lee, Yu Ru Kou & Diahn-Warng Perng. (2018) Glycopyrronium bromide inhibits lung inflammation and small airway remodeling induced by subchronic cigarette smoke exposure in mice. Respiratory Physiology & Neurobiology 249, pages 16-22.
Crossref
Crossref
Marc Miravitlles, Gerard Urrutia, Alexander G. Mathioudakis & Julio Ancochea. (2017) Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. Respiratory Research 18:1.
Crossref
Crossref
Mario Cazzola & Paola Rogliani. (2017) Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. Journal of Comparative Effectiveness Research 6:7, pages 627-636.
Crossref
Crossref